BIMEKIZUMAB REAL-WORLD USE IN PSORIASIS: INSIGHTS FROM A MULTICENTER, MULTI-YEAR RETROSPECTIVE COHORT STUDY IN SPAIN, RESULTS FROM THE RUBIES STUDY
Author(s)
Jorge Magdaleno Tapial, PhD1, Pablo de la Cueva, PhD2, Raquel Rivera Díaz, PhD3, Rosa Mª Izu Belloso, PhD4, Anna López Ferrer, PhD5, Nicolás Silvestre Torner, PhD6, Jose Luis Lopez Estebaranz, PhD7, Dionysis Spanopoulos, PhD8, Ana Barbadillo Ruiz, MSc9, Isabelle Fovel, Ir10, Nathalie van Hemert, MSc11, Philine E.A. Adolfsen, MSc12, Jasper Deuring, PhD12.
1Consorcio Hospital General Universitario de València, Valencia, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Hospital Universitario Basurto, Pais Vasco, Spain, 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6Hospital Universitario Severo Ochoa, Madrid, Spain, 7Hospital Universitario Fundación Alcorcón, Madrid, Spain, 8UCB, Slough, United Kingdom, 9UCB, Madrid, Spain, 10UCB, Brussels, Belgium, 11LOGEX, Leiden, Netherlands, 12LOGEX, Amsterdam, Netherlands.
1Consorcio Hospital General Universitario de València, Valencia, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Hospital Universitario 12 de Octubre, Madrid, Spain, 4Hospital Universitario Basurto, Pais Vasco, Spain, 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6Hospital Universitario Severo Ochoa, Madrid, Spain, 7Hospital Universitario Fundación Alcorcón, Madrid, Spain, 8UCB, Slough, United Kingdom, 9UCB, Madrid, Spain, 10UCB, Brussels, Belgium, 11LOGEX, Leiden, Netherlands, 12LOGEX, Amsterdam, Netherlands.
OBJECTIVES: Real world data are needed to contextualize biologic treatment positioning in psoriasis. This study evaluated Bimekizumab, a dual IL-17A/IL-17F inhibitor, use in routine clinical practice in Spain, by describing patient characteristics, prior rheumatology visits, treatment pathways, time-to-next-treatment, and maintenance dosing patterns versus the label.
METHODS: RUBIES is a multicenter retrospective-cohort study using routinely collected data from a Spanish psoriasis-observatory. Inclusion: adults initiating biologics between January 2020 and June 2025. The baseline characteristics, treatment history and prior rheumatology visits are described; among bimekizumab initiators, time-to-next-treatment and maintenance dosing intervals versus the EMA label were evaluated.
RESULTS: A total 4,787 patients initiated a new biologic, of which 332 initiated bimekizumab. Of these bimekizumab initiations, 14.2% were biologic-naïve, 29.5% had received one prior biologic treatment, and 56.3% had been exposed to 2+ prior biologic treatments. Patients initiating IL-17A (48.8%) or dual IL-17A/IL17F (48.5%) inhibitors, had a higher prevalence of prior rheumatology department visits in the year preceding initiation compared with those initiating IL-23 (27.2%) and IL12/23 inhibitors (20.3%).
Time-to-event analysis showed over 75% of patients did not switch biologics, for at least 1.5 years, following bimekizumab initiation. In the maintenance phase, ~70% of bimekizumab patients received dosing at intervals concordant with the EMA‑approved regimen.
CONCLUSIONS: In routine clinical practice in Spain, bimekizumab is initiated across all lines of therapy. Despite heterogeneous treatment histories, over three-quarters of patients did not switch to another biologic after 1.5 years, and maintenance dosing was largely according to EMA-label. Higher prevalence of rheumatology visits among patients initiating IL-17A and IL-17A/IL17F inhibitors, suggests use of these treatments in patients with potential rheumatologic comorbidities. These findings underscore the value of longitudinal, multicenter RWD for characterizing psoriasis patient pathways.
METHODS: RUBIES is a multicenter retrospective-cohort study using routinely collected data from a Spanish psoriasis-observatory. Inclusion: adults initiating biologics between January 2020 and June 2025. The baseline characteristics, treatment history and prior rheumatology visits are described; among bimekizumab initiators, time-to-next-treatment and maintenance dosing intervals versus the EMA label were evaluated.
RESULTS: A total 4,787 patients initiated a new biologic, of which 332 initiated bimekizumab. Of these bimekizumab initiations, 14.2% were biologic-naïve, 29.5% had received one prior biologic treatment, and 56.3% had been exposed to 2+ prior biologic treatments. Patients initiating IL-17A (48.8%) or dual IL-17A/IL17F (48.5%) inhibitors, had a higher prevalence of prior rheumatology department visits in the year preceding initiation compared with those initiating IL-23 (27.2%) and IL12/23 inhibitors (20.3%).
Time-to-event analysis showed over 75% of patients did not switch biologics, for at least 1.5 years, following bimekizumab initiation. In the maintenance phase, ~70% of bimekizumab patients received dosing at intervals concordant with the EMA‑approved regimen.
CONCLUSIONS: In routine clinical practice in Spain, bimekizumab is initiated across all lines of therapy. Despite heterogeneous treatment histories, over three-quarters of patients did not switch to another biologic after 1.5 years, and maintenance dosing was largely according to EMA-label. Higher prevalence of rheumatology visits among patients initiating IL-17A and IL-17A/IL17F inhibitors, suggests use of these treatments in patients with potential rheumatologic comorbidities. These findings underscore the value of longitudinal, multicenter RWD for characterizing psoriasis patient pathways.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HSD53
Topic
Health Service Delivery & Process of Care, Study Approaches
Disease
Biologics & Biosimilars